Literature DB >> 2498389

Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis.

S S Pedersen1, F Espersen, N Høiby, G H Shand.   

Abstract

Alginates from nine mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis were purified by repeated ethanol precipitation, nuclease digestion, anion-exchange chromatography, dialysis, and lyophilization. Uronic acid constituted 72% of the dry weight when mannuronolactone was used as the internal standard in the carbazole-borate assay for uronic acids. The average degree of acetylation was 16%, and the ratio of mannuronic acid to gluluronic acid was 4.7. No homopolymeric blocks of guluronic acid were found when analyzed by nuclear magnetic resonance spectroscopy. Contaminating proteins were denatured by heating, and during purification the content of protein relative to alginate fell from 566 to 0.9%. The content of lipopolysaccharide was 0.012%. No immunological or biological activity was attributable to the protein or lipopolysaccharide content as estimated by immunoblotting, enzyme-linked immunosorbent assay (ELISA), and a neutrophil chemotaxis assay. Rabbits were hyperimmunized with P. aeruginosa alginates and alginate from the seaweed Laminaria hyperborea, and an ELISA that detected alginate-specific antibodies was developed. Antibodies to P. aeruginosa alginate were detected by ELISA in 1:4,000 dilutions of serum from patients with cystic fibrosis with chronic P. aeruginosa lung infection. The serological cross-reactions between serum from the nine patients with cystic fibrosis and the corresponding P. aeruginosa alginates were investigated and showed considerable heterogeneity. This finding indicates that P. aeruginosa alginate from more than one P. aeruginosa strain should be used in serological tests. There was no serological cross-reactivity between P. aeruginosa and Laminaria hyperborea alginate in either rabbits or patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498389      PMCID: PMC267399          DOI: 10.1128/jcm.27.4.691-699.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  44 in total

1.  Monomer sequence and acetylation pattern in some bacterial alginates.

Authors:  G Skjåk-Braek; H Grasdalen; B Larsen
Journal:  Carbohydr Res       Date:  1986-10-15       Impact factor: 2.104

2.  Antibody to multiple mucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis, measured by an enzyme-linked immunosorbent assay.

Authors:  R S Baltimore; R B Fick; L Fino
Journal:  Pediatr Res       Date:  1986-11       Impact factor: 3.756

3.  Association of alginate from Pseudomonas aeruginosa with two forms of heparin-binding lectin isolated from rat lung.

Authors:  H Ceri; H A McArthur; C Whitfield
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

4.  Prevalence of mucoid strains of Pseudomonas aeruginosa in bacteriological specimens from patients with cystic fibrosis and patients with other diseases.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1975-12

5.  Nonspecific staining of mast cells by avidin-biotin-peroxidase complexes (ABC).

Authors:  G Bussolati; P Gugliotta
Journal:  J Histochem Cytochem       Date:  1983-12       Impact factor: 2.479

6.  A new polysaccharide resembling alginic acid isolated from pseudomonads.

Authors:  A Linker; R S Jones
Journal:  J Biol Chem       Date:  1966-08-25       Impact factor: 5.157

7.  The purification and chemical characterisation of the alginate present in extracellular material produced by mucoid strains of Pseudomonas aeruginosa.

Authors:  V Sherbrock-Cox; N J Russell; P Gacesa
Journal:  Carbohydr Res       Date:  1984-12-15       Impact factor: 2.104

8.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors:  G B Pier; W J Matthews; D D Eardley
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

9.  Production and characterization of the slime polysaccharide of Pseudomonas aeruginosa.

Authors:  L R Evans; A Linker
Journal:  J Bacteriol       Date:  1973-11       Impact factor: 3.490

10.  Polyclonal B cell stimulation and interleukin 1 induction by the mucoid exopolysaccharide of Pseudomonas aeruginosa associated with cystic fibrosis.

Authors:  L Daley; G B Pier; J D Liporace; D D Eardley
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

View more
  21 in total

1.  Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms.

Authors:  E T Jensen; A Kharazmi; K Lam; J W Costerton; N Høiby
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

2.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

3.  Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.

Authors:  S S Pedersen; A Kharazmi; F Espersen; N Høiby
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  The sigma factor AlgU (AlgT) controls exopolysaccharide production and tolerance towards desiccation and osmotic stress in the biocontrol agent Pseudomonas fluorescens CHA0.

Authors:  U Schnider-Keel; K B Lejbølle; E Baehler; D Haas; C Keel
Journal:  Appl Environ Microbiol       Date:  2001-12       Impact factor: 4.792

5.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Alginate lyase exhibits catalysis-independent biofilm dispersion and antibiotic synergy.

Authors:  John W Lamppa; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

7.  Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice.

Authors:  Wan C Tsai; Marc B Hershenson; Ying Zhou; Umadevi Sajjan
Journal:  Inflamm Res       Date:  2009-03-07       Impact factor: 4.575

Review 8.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

9.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

10.  Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Authors:  T Pressler; J P Pandey; F Espersen; S S Pedersen; A Fomsgaard; C Koch; N Høiby
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.